| 11/30 | ANALYST RECOMMENDATIONS : Best Buy, Beyond Meat, Booking, Merck, Pfizer... | |
| 11/29 | SVB Leerink Adjusts Merck & Co.'s Price Target to $102 from $105, Keeps Outperform Rati.. | MT |
| 11/29 | Morgan Stanley Adjusts Merck & Co.'s Price Target to $82 from $88, Keeps Equalweight Ra.. | MT |
| 11/29 | ANALYST RECOMMENDATIONS : Asos, Burberry, Greif, Merck, Mirion Technologies.... | |
| 11/29 | Citigroup Cuts Merck & Co. to Neutral From Buy, Price Target to $85 From $105 | MT |
| 11/24 | Truist Securities Adjusts Merck's Price Target to $95 From $92, Reiterates Buy Rating | MT |
| 11/19 | BMO Capital Starts Merck at Market Perform With $91 Price Target | MT |
| 11/01 | Barclays Adjusts Price Target on Merck & Company to $94 From $92, Maintains Overweight .. | MT |
| 11/01 | Argus Upgrades Merck & Co. to Buy from Hold, Sets $110 Price Target | MT |
| 10/29 | Barclays Adjusts Price Target for Merck & Company to $94 From $92, Maintains Overweight | MT |
| 10/29 | Morgan Stanley Lifts Price Target on Merck to $90 From $88, Citing 'Strong' Q3, Higher .. | MT |
| 10/12 | MERCK : Morgan Stanley Adjusts Price Target on Merck & Company to $88 From $85, Maintains .. | MT |
| 10/08 | MERCK : Barclays Adjusts Merck & Co.'s Price Target to $92 from $87, Keeps Overweight Rati.. | MT |
| 10/08 | MERCK : Receives Price Target Boost to $92 From $86 From Berenberg Bank; Hold Rating Maint.. | MT |
| 10/05 | ANALYST RECOMMENDATIONS : Chipotle Mexican Grill, Coherent, Merck, Microchip Technology, V.. | |
| 10/04 | MERCK : Atlantic Equities Adjusts Merck & Company PT to $100 From $92, Maintains Overweigh.. | MT |
| 10/04 | MERCK : SVB Leerink Adjusts Price Target on Merck & Company to $104 From $101, Maintains O.. | MT |
| 09/08 | MERCK : Berenberg Bank Adjusts Merck & Company PT to $86 From $88, Maintains Hold Rating | MT |
| 09/07 | MERCK : Morgan Stanley Downgrades Merck & Company to Equalweight from Overweight, Adjusts .. | MT |
| 09/07 | ANALYST RECOMMENDATIONS : Amgen, Banner, Merck, Oracle, Phoenix... | |
| 07/30 | MERCK : Goldman Sachs Adjusts Price Target for Merck to $104 From $102, Maintains Buy Rati.. | MT |
| 07/30 | MERCK : SVB Leerink Adjusts Price Target on Merck & Company to $101 From $99, Maintains Ou.. | MT |
| 07/28 | ANALYST RECOMMENDATIONS : Flutter, Hasbro, MGM Resort, Microsoft Vodafone... | |
| 07/27 | MERCK : Truist Assumes Merck & Company at Buy Rating With $92 Price Target | MT |
| 07/14 | MERCK : RBC Lifts Price Target on Merck to $80 From $75 Ahead of Q2 Results, Reiterates Se.. | MT |
| 06/09 | MERCK : JPMorgan Adjusts Merck's Price Target to $100 From $105, Maintains Overweight Rati.. | MT |
| 06/08 | MERCK : Price Target From RBC Cut to $75 From $77 to Reflect Organon Spinoff, Sector Perfo.. | MT |
| 06/07 | MERCK : Truist Securities Adjusts Merck's Price Target to $93 From $96, Maintains Buy Rati.. | MT |
| 06/03 | MERCK : SVB Leerink Adjusts Merck & Co.'s Price Target to $99 from $102, Keeps Outperform .. | MT |
| 05/20 | MERCK : Argus Research Downgrades Merck & Company to Hold Rating From Buy | MT |
| 04/30 | MERCK : RBC Capital Adjusts Merck & Company PT to $77 From $79, Maintains Sector Perform R.. | MT |
| 2020 | MERCK : Bernstein Reinstates Merck & Co. at Outperform with $95 Price Target | MT |
| 2020 | MERCK : Expects Nearly $2 Billion Covid-19 Revenue Impact in 2020 | DJ |
| 2020 | Pharma Companies Split on Coronavirus Vaccine Pricing Plans | DJ |
| 2020 | MERCK & CO INC : RBC gives a Neutral rating | MD |
| 2019 | Bristol-Myers posts better-than-expected results, Opdivo growth slows | RE |
| 2019 | MERCK & CO INC : Goldman Sachs remains Neutral | MD |
| 2019 | MERCK & CO INC : JP Morgan remains Neutral | MD |
| 2019 | AstraZeneca Imfinzi combination fails advanced lung cancer study | RE |
| 2019 | Elanco to become No.2 in animal health with $7.6 billion Bayer deal | RE |
| 2019 | Elanco to become No.2 in animal health with $7.6 billion Bayer deal | RE |
| 2019 | Eliquis, Orencia sales propel Bristol-Myers to strong second quarter | RE |
| 2019 | Merck KGaA clinches $6.5 billion Versum takeover in bet on electrochemicals | RE |
| 2019 | Merck KGaA clinches $6.5 billion Versum takeover in bet on electrochemicals | RE |
| 2019 | Biogen scraps two Alzheimer drug trials, wipes $18 billion from market value | RE |
| 2018 | Pfizer to replace longtime CEO Read with veteran Bourla | RE |
| 2018 | Pfizer to replace longtime CEO Read with veteran Bourla | RE |
| 2018 | Roche steps up efficiency drive to take sting out of biosimilars | RE |
| 2018 | Roundup cancer verdict sends Bayer shares sliding | RE |
| 2018 | Roundup cancer verdict sends Bayer shares sliding | RE |
| 2018 | Clamour for GSK shingles shot points to bigger profits | RE |
| 2018 | AstraZeneca cancer drug hits second goal by extending survival | RE |
| 2018 | Keytruda sales power Merck to quarterly beat | RE |
| 2018 | Keytruda sales power Merck to quarterly beat | RE |
| 2018 | GlaxoSmithKline prescribes commercial reboot for pharma division | RE |
| 2018 | GlaxoSmithKline prescribes commercial reboot for pharma division | RE |
| 2018 | Bristol-Myers to pay $1.85 billion in cancer deal with Nektar | RE |
| 2018 | U.S. tax change to help Roche's 2018 profit growth outpace sales | RE |
| 2017 | Roche drug cocktail doubles chance of holding lung cancer at bay | RE |
| 2017 | GSK wins U.S. shingles vaccine approval, UK nod for gene therapy | RE |
| 2017 | AstraZeneca shares surge after key drug shows promise in lung cancer trial | RE |
| 2017 | MERCK : 2017 forecast reassuring; full-speed ahead with Keytruda | RE |
| 2017 | Bristol-Myers lung cancer delay slams shares, keeps Merck in lead | RE |
| 2017 | Bristol-Myers shares fall on lung cancer timeline setback | RE |
| 2016 | Pharma, biotech shares soar as Trump win calms pricing talk | RE |
| 2016 | Pharma, biotech shares soar as Trump win calms pricing talk | RE |
| 2016 | Drugmakers under fire for possible U.S. price fixing | RE |
| 2016 | Bristol lung-cancer setback puts rival Merck drug in driver seat | RE |
| 2016 | MERCK : China's drugs watchdog struggles as senior staff lured away by industry | RE |
| 2016 | BRISTOL MYERS SQUIBB : Merck sales disappoint as Januvia, Remicade fall short | RE |
| 2016 | Merck gives cautious 2016 outlook as sales of top medicines lag | RE |
| 2015 | Merck profit tops estimates on strong diabetes, cancer drug sales | RE |
| 2015 | Wall St. ends lower with oil prices, renewed Greece worries | RE |
| 2014 | Pfizer dampens Astra bid hopes with German Merck cancer deal | RE |
| 2014 | ASTRAZENECA : touts independence as Nexium drug keeps on giving | RE |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
